Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 0.39
IPXL's Cash to Debt is ranked lower than
77% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.66 vs. IPXL: 0.39 )
Ranked among companies with meaningful Cash to Debt only.
IPXL' s 10-Year Cash to Debt Range
Min: 0.39  Med: 9999.00 Max: No Debt
Current: 0.39
Equity to Asset 0.50
IPXL's Equity to Asset is ranked lower than
68% of the 562 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. IPXL: 0.50 )
Ranked among companies with meaningful Equity to Asset only.
IPXL' s 10-Year Equity to Asset Range
Min: 0.2  Med: 0.54 Max: 0.84
Current: 0.5
0.2
0.84
Interest Coverage 2065.49
IPXL's Interest Coverage is ranked higher than
50% of the 374 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2065.49 vs. IPXL: 2065.49 )
Ranked among companies with meaningful Interest Coverage only.
IPXL' s 10-Year Interest Coverage Range
Min: 0.82  Med: 460.35 Max: 9999.99
Current: 2065.49
0.82
9999.99
F-Score: 7
Z-Score: 3.52
M-Score: -1.77
WACC vs ROIC
10.08%
7.83%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 11.88
IPXL's Operating margin (%) is ranked higher than
63% of the 658 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.76 vs. IPXL: 11.88 )
Ranked among companies with meaningful Operating margin (%) only.
IPXL' s 10-Year Operating margin (%) Range
Min: -1418.74  Med: 0.31 Max: 44.72
Current: 11.88
-1418.74
44.72
Net-margin (%) 7.19
IPXL's Net-margin (%) is ranked higher than
55% of the 659 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.90 vs. IPXL: 7.19 )
Ranked among companies with meaningful Net-margin (%) only.
IPXL' s 10-Year Net-margin (%) Range
Min: -1376.35  Med: 8.61 Max: 46
Current: 7.19
-1376.35
46
ROE (%) 5.11
IPXL's ROE (%) is ranked lower than
53% of the 685 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.19 vs. IPXL: 5.11 )
Ranked among companies with meaningful ROE (%) only.
IPXL' s 10-Year ROE (%) Range
Min: -341.31  Med: 6.76 Max: 125.75
Current: 5.11
-341.31
125.75
ROA (%) 3.72
IPXL's ROA (%) is ranked higher than
53% of the 705 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. IPXL: 3.72 )
Ranked among companies with meaningful ROA (%) only.
IPXL' s 10-Year ROA (%) Range
Min: -70.9  Med: 3.10 Max: 38.8
Current: 3.72
-70.9
38.8
ROC (Joel Greenblatt) (%) 21.30
IPXL's ROC (Joel Greenblatt) (%) is ranked higher than
64% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.97 vs. IPXL: 21.30 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
IPXL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -297.18  Med: 26.33 Max: 236.29
Current: 21.3
-297.18
236.29
Revenue Growth (3Y)(%) 3.50
IPXL's Revenue Growth (3Y)(%) is ranked lower than
60% of the 541 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. IPXL: 3.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
IPXL' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 44.20 Max: 203.4
Current: 3.5
0
203.4
EBITDA Growth (3Y)(%) 1.60
IPXL's EBITDA Growth (3Y)(%) is ranked lower than
58% of the 483 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.80 vs. IPXL: 1.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
IPXL' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -14.95 Max: 61.6
Current: 1.6
0
61.6
EPS Growth (3Y)(%) -5.80
IPXL's EPS Growth (3Y)(%) is ranked lower than
63% of the 451 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. IPXL: -5.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
IPXL' s 10-Year EPS Growth (3Y)(%) Range
Min: -32.2  Med: -6.05 Max: 55.1
Current: -5.8
-32.2
55.1
» IPXL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

IPXL Guru Trades in Q2 2014

NWQ Managers 984,841 sh (New)
John Hussman 310,000 sh (+40.91%)
Paul Tudor Jones 18,000 sh (unchged)
Jim Simons Sold Out
RS Investment Management 940,950 sh (-29.17%)
» More
Q3 2014

IPXL Guru Trades in Q3 2014

Joel Greenblatt 33,709 sh (New)
Jim Simons 39,400 sh (New)
Paul Tudor Jones 36,853 sh (+104.74%)
NWQ Managers 1,298,995 sh (+31.90%)
RS Investment Management 809,959 sh (-13.92%)
John Hussman 250,000 sh (-19.35%)
» More
Q4 2014

IPXL Guru Trades in Q4 2014

Mario Gabelli 6,775 sh (New)
Alan Fournier 533,100 sh (New)
Joel Greenblatt 79,609 sh (+136.17%)
Jim Simons 61,400 sh (+55.84%)
Paul Tudor Jones 39,050 sh (+5.96%)
John Hussman 250,000 sh (unchged)
RS Investment Management Sold Out
NWQ Managers 906,043 sh (-30.25%)
» More
Q1 2015

IPXL Guru Trades in Q1 2015

George Soros 61,206 sh (New)
Alan Fournier 2,025,000 sh (+279.85%)
Jim Simons 71,900 sh (+17.10%)
NWQ Managers 936,127 sh (+3.32%)
John Hussman 250,000 sh (unchged)
Joel Greenblatt Sold Out
Mario Gabelli Sold Out
Paul Tudor Jones 9,300 sh (-76.18%)
» More
» Details

Insider Trades

Latest Guru Trades with IPXL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 76.43
IPXL's P/E(ttm) is ranked lower than
78% of the 472 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.90 vs. IPXL: 76.43 )
Ranked among companies with meaningful P/E(ttm) only.
IPXL' s 10-Year P/E(ttm) Range
Min: 4.04  Med: 45.75 Max: 1043
Current: 76.43
4.04
1043
Forward P/E 22.08
IPXL's Forward P/E is ranked higher than
56% of the 233 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.27 vs. IPXL: 22.08 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 77.90
IPXL's PE(NRI) is ranked lower than
78% of the 472 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.00 vs. IPXL: 77.90 )
Ranked among companies with meaningful PE(NRI) only.
IPXL' s 10-Year PE(NRI) Range
Min: 4.04  Med: 45.64 Max: 1043
Current: 77.9
4.04
1043
P/B 3.87
IPXL's P/B is ranked lower than
53% of the 671 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.55 vs. IPXL: 3.87 )
Ranked among companies with meaningful P/B only.
IPXL' s 10-Year P/B Range
Min: 1.32  Med: 2.95 Max: 12.8
Current: 3.87
1.32
12.8
P/S 5.49
IPXL's P/S is ranked lower than
67% of the 649 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.43 vs. IPXL: 5.49 )
Ranked among companies with meaningful P/S only.
IPXL' s 10-Year P/S Range
Min: 1.17  Med: 3.13 Max: 12.72
Current: 5.49
1.17
12.72
PFCF 89.39
IPXL's PFCF is ranked lower than
69% of the 275 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 49.38 vs. IPXL: 89.39 )
Ranked among companies with meaningful PFCF only.
IPXL' s 10-Year PFCF Range
Min: 1.96  Med: 16.08 Max: 93.85
Current: 89.39
1.96
93.85
POCF 45.98
IPXL's POCF is ranked lower than
66% of the 384 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 29.86 vs. IPXL: 45.98 )
Ranked among companies with meaningful POCF only.
IPXL' s 10-Year POCF Range
Min: 1.75  Med: 13.70 Max: 2002
Current: 45.98
1.75
2002
EV-to-EBIT 49.31
IPXL's EV-to-EBIT is ranked lower than
74% of the 486 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.52 vs. IPXL: 49.31 )
Ranked among companies with meaningful EV-to-EBIT only.
IPXL' s 10-Year EV-to-EBIT Range
Min: -642.3  Med: 33.10 Max: 216.9
Current: 49.31
-642.3
216.9
Shiller P/E 30.05
IPXL's Shiller P/E is ranked higher than
60% of the 310 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 39.83 vs. IPXL: 30.05 )
Ranked among companies with meaningful Shiller P/E only.
IPXL' s 10-Year Shiller P/E Range
Min: 10.23  Med: 19.82 Max: 61.99
Current: 30.05
10.23
61.99
Current Ratio 2.44
IPXL's Current Ratio is ranked higher than
53% of the 608 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. IPXL: 2.44 )
Ranked among companies with meaningful Current Ratio only.
IPXL' s 10-Year Current Ratio Range
Min: 1.12  Med: 3.75 Max: 10.65
Current: 2.44
1.12
10.65
Quick Ratio 1.95
IPXL's Quick Ratio is ranked higher than
56% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. IPXL: 1.95 )
Ranked among companies with meaningful Quick Ratio only.
IPXL' s 10-Year Quick Ratio Range
Min: 0.63  Med: 3.04 Max: 10.07
Current: 1.95
0.63
10.07
Days Inventory 107.01
IPXL's Days Inventory is ranked higher than
55% of the 621 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.49 vs. IPXL: 107.01 )
Ranked among companies with meaningful Days Inventory only.
IPXL' s 10-Year Days Inventory Range
Min: 50.25  Med: 96.02 Max: 398.94
Current: 107.01
50.25
398.94
Days Sales Outstanding 106.08
IPXL's Days Sales Outstanding is ranked lower than
73% of the 592 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.86 vs. IPXL: 106.08 )
Ranked among companies with meaningful Days Sales Outstanding only.
IPXL' s 10-Year Days Sales Outstanding Range
Min: 34.05  Med: 85.17 Max: 1169.47
Current: 106.08
34.05
1169.47

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 3.23
IPXL's Price/Projected FCF is ranked higher than
50% of the 321 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.23 vs. IPXL: 3.23 )
Ranked among companies with meaningful Price/Projected FCF only.
IPXL' s 10-Year Price/Projected FCF Range
Min: 1  Med: 1.69 Max: 3.82
Current: 3.23
1
3.82
Price/Median PS Value 1.78
IPXL's Price/Median PS Value is ranked lower than
67% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.40 vs. IPXL: 1.78 )
Ranked among companies with meaningful Price/Median PS Value only.
IPXL' s 10-Year Price/Median PS Value Range
Min: 0.43  Med: 1.20 Max: 26.88
Current: 1.78
0.43
26.88
Earnings Yield (Greenblatt) (%) 2.05
IPXL's Earnings Yield (Greenblatt) (%) is ranked lower than
52% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. IPXL: 2.05 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
IPXL' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.5  Med: 2.30 Max: 55.9
Current: 2.05
0.5
55.9
Forward Rate of Return (Yacktman) (%) -21.10
IPXL's Forward Rate of Return (Yacktman) (%) is ranked lower than
91% of the 308 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.88 vs. IPXL: -21.10 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
IPXL' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -22.1  Med: 0.95 Max: 144.8
Current: -21.1
-22.1
144.8

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:ILR.Germany,
Impax Laboratories Inc is a Delaware corporation was incorporated in 1995. It is a technology-based, specialty pharmaceutical company applying formulation and development expertise, as well as its drug delivery technology, to the development, manufacture and marketing of bioequivalent pharmaceutical products, commonly referred to as 'generics' in addition to the development and marketing of branded products. The Company operates in two segments namely Global Pharmaceuticals Division and Impax Pharmaceuticals Division. The Global Division develops, manufactures, sells and distributes its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are usually marketed under their established nonproprietary drug names rather than by a brand name. The Company develops, manufacture, sell and distribute specialty generic pharmaceuticals. The Global Division develops, manufactures, sells, and distributes generic pharmaceutical products mainly through four sales channels: the 'Global products' sales channel, for generic pharmaceutical prescription products the Company sells directly to wholesalers, large retail drug chains, and others; the 'Private Label' sales channel, for generic pharmaceutical over-the-counter ('OTC') and prescription products the Company sells to unrelated third-party customers who in-turn sell the product to third parties under its own label; the 'Rx Partner' sales channel, for generic prescription products sold through unrelated third-party pharmaceutical entities under its own label pursuant to alliance agreements; and the 'OTC Partner' sales channel, for sales of generic pharmaceutical OTC products sold through unrelated third-party pharmaceutical entities under its own label pursuant to alliance agreements. The Impax Division is engaged in the development of proprietary brand pharmaceutical products. The Impax Division is also engaged in the sale and distribution of branded Zomig(r) (zolmitriptan) products, indicated for the treatment of migraine headaches, under the terms of a Distribution, License, Development and Supply Agreement (AZ Agreement) with AstraZeneca UK Limited (AstraZeneca). The Company's Impax Division develops proprietary brand pharmaceutical products through improvements to already approved pharmaceutical products to address central nervous system ('CNS') disorders. The Impax Division is also engaged in the co-promotion through a direct sales force focused on marketing to physicians, mainly in the CNS community, pharmaceutical products developed by other unrelated third-party pharmaceutical entities. The Company markets and sells its generic pharmaceutical prescription drug products within the continental United States of America and the Commonwealth of Puerto Rico. The chemical raw materials, essential to its business, are generally readily available from multiple sources in the U.S. and throughout the world. Generic pharmaceutical product develop
» More Articles for IPXL

Headlines

Articles On GuruFocus.com
Alan Fournier's Highest Performing Stocks Jul 15 2015 
Alan Fournier's Most Heavily Weighted Trades In Q1 2015 May 28 2015 
Impax Laboratories Inc. Steps Into Profitable Zone Feb 26 2015 
comment on IPXL Sep 24 2012 
President and CEO of Impax Laboratories Inc. (IPXL) Larry Hsu Bought 10,000 Shares Aug 17 2011 
Impax Laboratories Inc. (IPXL) CEO Larry Hsu buys 5,000 Shares Aug 12 2010 
Impax Laboratories Inc. (IPXL) CEO Larry Hsu buys 10,000 Shares Aug 12 2010 
Impax Laboratories Reports Second Quarter 2009 Financial Results Aug 04 2009 

More From Other Websites
Hikma Pharmaceuticals Plc: Strong price momentum but will it sustain? Jul 29 2015
Coverage initiated on Impax Labs by Susquehanna Jul 21 2015
IMPAX LABORATORIES INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders,... Jul 08 2015
Impax to Report Second Quarter 2015 Results on August 10, 2015 Jul 06 2015
Impax to Report Second Quarter 2015 Results on August 10, 2015 Jul 06 2015
Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors Jul 06 2015
Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors Jul 06 2015
IMPAX LABORATORIES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination... Jun 30 2015
Alan Fournier Sells Stake in Gilead Sciences Jun 25 2015
IMPAX LABORATORIES INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 25 2015
Impax Laboratories, Inc. Prices Private Offering of Convertible Senior Notes Jun 25 2015
Impax Laboratories, Inc. Prices Private Offering of Convertible Senior Notes Jun 25 2015
Keep An Eye On These 10 After-Hours Movers Jun 25 2015
IMPAX LABORATORIES INC Files SEC form 8-K, Regulation FD Disclosure, Other Events Jun 24 2015
Impax Laboratories, Inc. Announces Private Offering of Convertible Senior Notes Jun 24 2015
Impax Laboratories, Inc. Announces Private Offering of Convertible Senior Notes Jun 24 2015
Impax's Zomig Nasal Spray Gets FDA Nod for Pediatrics - Analyst Blog Jun 17 2015
FDA Approves ZOMIG® (zolmitriptan) Nasal Spray for Migraine in Pediatric Patients (Ages 12-17) Jun 16 2015
Impax to Present at the Goldman Sachs 36th Annual Global Healthcare Conference Jun 04 2015
Impax to Present at the Goldman Sachs 36th Annual Global Healthcare Conference Jun 04 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK